GTS Securities’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-19,150
Closed -$2.98M 1495
2024
Q3
$2.98M Sell
19,150
-2,000
-9% -$323K 0.01% 1276
2024
Q2
$3.3M Sell
21,150
-21,650
-51% -$3.26M 0.01% 1132
2024
Q1
$5.8M Buy
42,800
+20,150
+89% +$2.67M 0.01% 761
2023
Q4
$3.05M Sell
22,650
-20,450
-47% -$2.66M 0.01% 1340
2023
Q3
$5.84M Buy
+43,100
New +$5.89M 0.01% 849

Other funds holding AZN

GTS Securities's AZN Position: Q1 2026 in Review

GTS Securities increased its AstraZeneca (AZN) stake by 396% in Q1 2026, buying an estimated $1M and bringing the position to 6,500 shares worth $1.28M. The position accounts for 0.05% of the portfolio, ranked #305.

GTS Securities first reported a position in AZN in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.74M in Q2 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • GTS Securities held 6,500 shares of AstraZeneca worth $1.28M as of Q1 2026.
  • GTS Securities bought 5,190 AstraZeneca shares in Q1 2026, an estimated $1M.
  • AstraZeneca made up 0.05% of GTS Securities's portfolio in Q1 2026, its #305 holding.
  • GTS Securities first reported a position in AstraZeneca in Q3 2023 and has held it in 10 quarters since.
  • GTS Securities's AstraZeneca position peaked at $4.74M in Q2 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.